Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913188 | 0.92 | ALOX5AP (0.38) | ALOX5APFEN1ERN1GPR3GRM2 | |
| SCHEMBL18746886 | 0.92 | ALOX5AP (0.36) | ALOX5APFEN1 | |
| SCHEMBL15388222 | 0.88 | ALOX5AP (0.41) | ALOX5APFEN1ERN1GPR3CYP1A2 | |
| SCHEMBL19557550 | 0.86 | ALOX5AP (0.38) | ALOX5APFEN1ERN1GPR3CYP1A2 | |
| SCHEMBL19557556 | 0.86 | ALOX5AP (0.38) | ALOX5APFEN1ERN1GPR3CYP1A2 | |
| SCHEMBL12226114 | 0.85 | GPR3 (0.40) | ALOX5APFEN1ERN1GPR3CYP1A2 | |
| SCHEMBL14235285 | 0.84 | ALOX5AP (0.39) | ALOX5APFEN1ERN1GPR3GRM2 | |
| SCHEMBL2395180 | 0.83 | — | — | |
| SCHEMBL12760431 | 0.83 | ALOX5AP (0.36) | ALOX5APFEN1 | |
| SCHEMBL15388497 | 0.83 | ERN1 (0.40) | ALOX5APFEN1ERN1GPR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668174-B1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2668174-B1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-20130306908-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-20130306908-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | ALOX5AP 1014/4885FEN1 3980/4885ERN1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.